Addition of other diagnostic biomarkers such as markers of inflammation (e.g., soluble ST2 receptor), oxidative stress (e.g., growth differentiation factor-15) and cardiac remodeling (e.g., galectin-3) can be beneficial in guiding HF therapy (17). This evidence concerns the gene GDF15 and hydrops fetalis.